Skip to main content

Table 3 Patients with AEs up to month 12 (safety population)

From: Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial

AE

Observation group (n = 11)

Control group (n = 11)

Overall

7 (63.6%)

11 (100%)

AEs

Pyrexia

3 (27.3%)

4 (36.4%)

Perianal pain

7 (63.6%)

11 (100%)

Anal abscess/fistula

3 (27.3%)

5 (45.5%)

Fatigue

4 (36.4%)

8 (72.7%)

AEs leading to study withdrawal

2 (18.2%)

3 (27.3%)

Treatment-related AEs

0 (0%)

11 (100%)

Perianal pain

0 (0%)

11 (100%)

Anal abscess/fistula

0 (0%)

1 (9.1%)

Serious AEs

0 (0%)

0 (0%)